Medical

Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection in lung transplant patients infected with respiratory syncytial virus (RSV) in an “intent-to-treat” (ITTc) analysis, but that it met … [Read more...] about Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study

Boehringer Ingelheim has presented data from studies of olodaterol and tiotropium at the 2012 Annual Meeting of the American Thoracic Society. According to the company, it has now completed its Phase 2 trials of olodaterol, delivered via the Respimat soft mist inhaler, as a monotherapy for COPD, and that Phase 3 trials are also complete. BI is also developing a fixed … [Read more...] about Boehringer Ingelheim announces results from studies of olodaterol and tiotropium

US Health and Human Services Secretary Kathleen Sebelius has announced a national plan to fight Alzheimer’s disease that includes almost $8 million in funding for research related to an insulin nasal spray for the treatment of the disease. An article published in the Archives of Neurology in September 2011 described positive results from the SNIFF (Study of Nasal … [Read more...] about US plan to fight Alzheimer’s includes funding for development of insulin nasal spray

Elevation Pharmaceuticals has announced that a Phase 2b study of its EP-101 glycopyrrolate inhalation solution in patients with moderate to severe COPD demonstrated that EP-101 produced statistically significant improvement in lung function compared to placebo after 7 days. The GOLDEN-1 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) study … [Read more...] about Positive Phase 2b results for Elevation’s glycopyrrolate inhalation solution

Data from the Centers for Disease Control and Prevention (CDC) Asthma Call-back Survey show that 18.7 million US adults (8.2 percent) have asthma today out of approximately 29.1 million adults (12.7 percent) who have been diagnosed with asthma at some point in their lifetimes. The data are contained in a report called Asthma’s Impact on the Nation. According to the … [Read more...] about CDC survey shows that almost 19 million US adults have asthma

Pulmatrix is presenting two posters at RDD, one titled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology,” and the other titled “Development of an iSPERSE Based Platform for the Delivery of Macromolecules via Dry Powder Formulations.” The posters include data from in vitro and preclinical studies of formulations … [Read more...] about Pulmatrix touts iSPERSE potential for inhaled therapies

Aptar Pharma is presenting results from a clinical study of patient ability to use its Prohaler DPI at RDD this week. The study, which was conducted by Professor Patrice Diot at the Centre Hospitalier Regional Universitaire (CHRU) in Tours, France, demonstrated that all of the asthma and COPD patients involved in the study, no matter how ill, were able to trigger the … [Read more...] about Study confirms ergonomic advantages of Aptar inhaler

Liquidia Technologies has announced results from two studies of inhalation formulations created using the company’s PRINT (Particle Replication In Non-Wetting Templates) particle engineering technology. One study, published in the 2012 issue of the Journal of Drug Delivery, compared aerodynamic properties of PRINT-zanamivir inhalation powder to Relenza; the other, … [Read more...] about Liquidia publishes data from studies of inhalation formulations created with its particle engineering technology